<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">314</article-id><article-id pub-id-type="doi">10.25208/0042-4609-2017-93-3-10-20</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT COMMUNICATION</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">AUTOIMMUNE BULLOUS DERMATOSES. DIFFERENTIAL DIAGNOSIS</article-title><trans-title-group xml:lang="ru"><trans-title>АУТОИММУННЫЕ БУЛЛЕЗНЫЕ ДЕРМАТОЗЫ. ДИФФЕРЕНЦИАЛЬНЫЙ ДИАГНОЗ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Al'banova</surname><given-names>V. I.</given-names></name><name xml:lang="ru"><surname>Альбанова</surname><given-names>В. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Korolenko str., 3, bldg 6, Moscow, 107076, Russia</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, ведущий научный сотрудник отдела дерматологии ФГБУ «ГНЦДК» Минздрава России, Москва; 107076, г. Москва, ул. Короленко, д. 3, стр. 6</p></bio><email>albanova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nefedova</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Нефедова</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Korolenko str., 3, bldg 6, Moscow, 107076, Russia</p></bio><bio xml:lang="ru"><p>младший научный сотрудник отдела дерматологии ФГБУ «ГНЦДК» Минздрава России, Москва; 107076, г. Москва, ул. Короленко, д. 3, стр. 6</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-06-09" publication-format="electronic"><day>09</day><month>06</month><year>2017</year></pub-date><volume>93</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>10</fpage><lpage>20</lpage><history><date date-type="received" iso-8601-date="2017-10-09"><day>09</day><month>10</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-10-09"><day>09</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Al'banova V.I., Nefedova M.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Альбанова В.И., Нефедова М.А.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Al'banova V.I., Nefedova M.A.</copyright-holder><copyright-holder xml:lang="ru">Альбанова В.И., Нефедова М.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/314">https://vestnikdv.ru/jour/article/view/314</self-uri><abstract xml:lang="en"><p>The review presents modern ideas concerning autoimmune bullous dermatoses (pemphigoid group): Duhring disease, bullous pemphigoid, cicatrizing pemphigus, pemphigoid gestationis, linear IgA bullous dermatosis and acquired bullous epidermolysis. Pathogenesis, clinical manifestations and modern methods of disease diagnostics are reported. Particular attention is paid to the diagnosis of acquired bullous epidermolysis, in which the leading role belongs to the reaction of immunofluorescence. The pathogenetic similarity between bullous pemphigoid, linear IgA dermatosis, cicatrizing pemphigoid and pemphigoid gestationis is shown, which allows us to regard them as a variety of a single pathological process.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре представлены современные представления об аутоиммунных буллезных дерматозах (пемфигоидной группе): герпетиформном дерматите Дюринга, буллезном пемфигоиде, рубцующем пемфигоиде, пемфигоиде беременных, линейном IgA дерматозе и приобретенном буллезном эпидермолизе. Освещены патогенез, клинические проявления и современные методы диагностики заболеваний. Особое внимание уделено диагностике приобретенного буллезного эпидермолиза, в которой ведущая роль принадлежит реакции иммунофлуоресценции. Показано патогенетическое сходство буллезного пемфигоида, линейного IgA дерматоза, рубцующего пемфигоида и пемфигоида беременных, что позволяет расценивать их как разновидности единого патологического процесса.</p></trans-abstract><kwd-group xml:lang="en"><kwd>autoimmune bullous dermatoses</kwd><kwd>pemphigoid group</kwd><kwd>Duhring disease</kwd><kwd>bullous pemphigoid</kwd><kwd>cicatrizing pemphigus</kwd><kwd>pemphigoid gestationis</kwd><kwd>herpes hestationis</kwd><kwd>linear IgA bullous dermatosis</kwd><kwd>acquired bullous epidermolysis</kwd><kwd>diagnostics</kwd><kwd>differential diagnosis</kwd><kwd>histologic study</kwd><kwd>reaction of immunofluorescence</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аутоиммунные буллезные дерматозы</kwd><kwd>пемфигоидная группа</kwd><kwd>герпетиформный дерматит</kwd><kwd>буллезный пемфигоид</kwd><kwd>рубцующий пемфигоид</kwd><kwd>пемфигоид беременных</kwd><kwd>герпес беременных</kwd><kwd>линейный IgA дерматоз</kwd><kwd>приобретенный буллезный эпидермолиз</kwd><kwd>диагностика</kwd><kwd>дифференциальный диагноз</kwd><kwd>гистологическое исследование</kwd><kwd>реакция иммунофлуоресценции</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Mihalyi L., Kiss M., Dobozy A. et al. Clinical relevance of autoantibodies in patients with autoimmune bullous dermatosis. Clinical and Developmental Immunology 2012; 2012: 369546.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Arbache S. T., Nogueira T.G., Delgado L. et al. Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience. Anais brasileiros de dermatologia 2014; 89(6): 885—889.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Schmidt E., Zillikens D. Pemphigoid diseases. Lancet. 2013; 381(9863): 320—332.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Karpati S. An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy. Dermatologic Clinics 2011; 29(3): 463-468.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Gawkrodger D.J., Blackwell J.N., Gilmour H.M. et al. Dermatitis herpetiformis diagnosis diet and demography. Gut 1984; 25(2):151—157.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Mobacken H., Kastrup W., Nilsson L. A. Incidence and prevalence of dermatitis herpetiformis in Sweden. Acta Dermato-venereologica 1984; 64(5): 400—404.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Salmi T. T., Hervonen K., Kautiainen H. et al. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol 2011;165(2): 354—359.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Federal clinical recommendations. Dermatovenereology 2015: Skin diseases. Sexually transmitted infections. 5th ed. M.: Delovoy Express, 2016, 768 pp. [Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд. М.: Деловой экспресс 2016; 768.]</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Jakes A. D., Bradley S., Donlevy L. Dermatitis herpetiformis. Br Med J 2014; 348: 2557.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Mendes F. B., Hissa-Elian A., Abreu M. A. et al. Review: dermatitis herpetiformis. Anais Brasileiros de Dermatologia 2013; 88(4): 594— 599.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Byrne G., Feighery C. F. Celiac Disease: Diagnosis. Methods in Molecular Biology 2015; 1326: 15—22.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Antiga E., Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clinical, Cosmetic and Investigational Dermatology 2015; 13(8): 257—265.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Rose C., Bröcker E. B., Zillikens D. Clinical, histological and immunpathological findings in 32 patients with dermatitis herpetiformis Duhring. Journal der Deutschen Dermatologischen Gesellschaft 2010; 8(4): 265—270.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Tsvetkova G. M., Mordovtsev V. V. et al. Pathomorphology of skin diseases: guidance for physicians. M: 2003, 496. [Цветкова Г. М., Мордовцев В. В. и др. Патоморфология бо- лезней кожи: руководство для врачей. М: 2003; 496.]</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Lever’s Histopathology of the Skin, 10th edition. David E. Elder, Editor-in-Chief, Philadelphia: Wolters Kluwer/Lippincott Williams &amp; Williams, 2008; 1408.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Warren S.J., Cockerell C.J. Characterization of a subgroup of patients with dermatitis herpetiformis with nonclassical histologic features. Am J Dermatopathol 2002; 24(4): 305—308.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Kalaaji A. N., Nicolas M. E. O. Mayo clinic atlas of immunofluorescence in dermatology: patterns and target antigens. CRC Press 2006.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Dieterich W., Laag E., Bruckner-Tuderman L. et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113(1): 133—136.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Kumar V., Jarzabek-Chorzelska M., Sulej J. et al. Tissue transglutaminase and endomysial antibodies-diagnostic markers of glutensensitive enteropathy in dermatitis herpetiformis. Clin Immunol 2001; 98(3): 378—382.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Jordon R. E., Beutner E. H., Witebsky E. et al. Basement zone antibodies in bullous pemphigoid. JAMA 1967; 200: 751—756.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Bagcı I. S., Horvath O. N., Ruzicka T. et al. Bullous pemphigoid. Autoimmunity Reviews. 2017 (in print).</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Bernard P., Antonicelli F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am J Clin Dermatol 2017 (in print).</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Schneider I., Husz S. Seborrhoic pemphigoid. Hautarzt. 1986; 37(3): 149—151.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Balestri R., Magnano M., La Placa M. et al. Malignancies in bullous pemphigoid: a controversial association. The Journal of dermatology. 2016; 43(2): 125—133.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Liu Z. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. The Keio journal of medicine. 2003; 52(2): 128—133.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Yamase A., Kono T., Ishii N. et al. An autoimmune bullous dermatosis with clinical, histopathological and immunological features of bullous pemphigoid and epidermolysis bullosa acquisita in an adult. Br J Dermatol 2016; 175(4): 790—793.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Terra J. B., Meijer J.M., Jonkman M. F. et al. The n- versus u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol 2013; 169(1): 100—105.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Edwards S., Wakelin S. H., Wojnarowska F. et al. Bullous pemphigoid and epidermolysis bullosa acquisita: Presentation, prognosis, and immunopathology in 11 children. Pediatr Dermatol 1998; 15: 184—190.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Yang B., Wang C., Chen S. et al. Accuracy of indirect immunofluorescence on sodium chloride-split skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Ind J Dermatol Venereol Leprol. 2011; 77(6): 677—682.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Feliciani C., Di Muzio M., Mohammad Pour S. et al. “Suction split” as a routine method to differentiate epidermolysis bullosa acquisita from bullous pemphigoid. J Eur Acad Dermatol Venereol 1998; 10(3): 243—247.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31. Ruhrberg C., Watt F.M. The plakin family: versatile organizers of cytoskeletal architecture. Current Opinion in Genetics and Development 1997; 7(3): 392—397.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32. Fortuna G., Marinkovich M. P. Linear immunoglobulin A bullous dermatosis. Clin Dermatol 2012; 30(1): 38—50.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33. Guide S. V., Marinkovich M. P. Linear IgA bullous dermatosis. Clin dermatol 2001; 19(6): 719—727.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34. Zone J.J. Clinical spectrum, pathogenesis and treatment of linear IgA bullous dermatosis. J dermatol 2001; 28(11): 651—653.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35. Eguia del Valle A., Aguirre Urízar J.M., Martínez Sahuquillo A. Oral manifestations caused by the linear IgA disease. Medicina oral: organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal. 2003; 9(1): 39—44.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36. Venning V. A. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Immunology and allergy clinics of North America. 2012; 32(2): 245—253.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37. Collier P.M., Kelly S. E., Wojnarowska F. Linear IgA disease and pregnancy. J Amer Acad Dermatol 1994; 30(3): 407—411.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38. Onodera H., Mihm M. C. Jr., Yoshida A. et al. Drug‐Induced Linear IgA Bullous Dermatosis. J Dermatol 2005; 32(9): 759—764.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39. Allen J., Phan T. T., Hughes M. A. et al. The cellular origins of the linear IgA disease target antigens: an indirect immunofluorescence study using cultured human keratinocytes and fibroblasts. Br J Dermatol 2003; 148(5): 945— 953.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40. Wozniak K., Hashimoto T., Ishii N. et al. Fluorescence overlay antigen mapping using laser scanning confocal microscopy differentiates linear IgA bullous dermatosis from epidermolysis bullosa acquisita mediated by IgA. Br J Dermatol 2013; 168(3): 634—638.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41. Roh J. Y., Yee C., Lazarova Z. et al. The 120‐ kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. Br J Dermatol 2000; 143(1): 104—111.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42. Kirzhner M., Jakobiec F. A. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management. Seminars in ophthalmology. Taylor &amp; Francis, 2011; 26 (4—5): 270—277.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43. Lin L., Zeng X., Chen Q. Pemphigus and pregnancy: Analysis and summary of case reports over 49 years. Saudi medical journal. 2015; 36(9): 1033—1038.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44. Jenkins R. E., Hern S., Black M.M. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Experiment Dermatol 1999; 24(4): 255—259.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45. Semkova K., Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstetrics Gynecol Reprod Biol 2009; 145(2): 138—144.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46. Al-Saif F., Elisa A., Al-Homidy A. et al. Retrospective analysis of pemphigoid gestationis in 32 Saudi patients — clinicopathological features and a literature review. J Reprod Immunol 2016; 116: 42—45.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>47. Baum S., Sakka N., Artsi O. et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmunity Reviews. 2014; 13: 482—489.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>48. Ludwig R.J. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol 2013; 2013: 812029.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>49. Gupta R., Woodley D. T., Chen M. Epidermolysis bullosa acquisita. Clin Dermatol 2012; 30: 60—69.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>50. Ishii N., Hamada T., Dainichi T. et al. Epidermolysis bullosa acquisita: What’s new? J Dermatol 2010; 37: 220—230.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>51. Chikin V. V., Znamenskaya L. F., Nefedova M. A. et al. Epidermolysis bullosa acquisita. Vestn Dermatol Venerol 2015; 3: 109—118. [Чикин В. В., Знаменская Л.Ф., Нефедова М. А. и соавт. Приобретенный буллезный эпидермолиз: описание клинического случая. Вестн дерматол венерол 2015; (3): 109—118.]</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>52. Albanova V. I., Nefedova M. A. Epidermolysis bullosa acquisita: diagnostic complexity. Vestn Dermatol Venerol 2017 (in print). [Альбанова В. И., Нефедова М. А. Приобретенный буллезный эпидермолиз: сложность диагностики. Вестн дерматол венерол 2017 (в печати).]</mixed-citation></ref></ref-list></back></article>
